Clinical Trials Browser

Has results × trilaciclib × Breast × Clear all

NCT05113966 2025-01-29

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Phase 2 Terminated

30 enrolled 16 charts

Triple Negative Breast Neoplasms

NCT05112536 2024-03-12

Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

Phase 2 Completed

24 enrolled 17 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02978716 2022-03-23

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)

Phase 2 Terminated

102 enrolled 51 charts

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms